
Summary of medications to treat depression^{1,2}

STARTING THERAPEUTIC **MEDICATIONS** PRESCRIBING TIPS DOSE DOSE Selective serotonin reuptake inhibitors (SSRIs) first-line medications because of a citalopram (Celexa) 20 mg 20 ma better safety profile compared to escitalopram (Lexapro) 5-10 mg 10-20 mg other antidepressants3 citalopram and escitalopram can sertraline (Zoloft) 25-50 mg 50-200 mg cause QTc prolongation long half-life may lead to fluoxetine (Prozac) 4-60 ma 10 ma accumulation anticholinergic effects limit use in paroxetine (Paxil) 10 mg 50 mg older adults Serotonin norepinephrine reuptake inhibitors (SNRIs) effective for co-occurring duloxetine (Cymbalta) 20-30 mg 60 mg neuropathic pain levomilnacipran 20 ma 40-120 ma (Fetzima) monitor for increase in blood venlafaxine (Effexor) 37.5-75 mg 150-225 mg pressure desvenlafaxine (Pristig) 25-50 mg 50-100 mg **Atypical antidepressants** can improve energy and concentration bupropion XL lowers appetite 150 mg 300 mg (Wellbutrin XL) helps with smoking cessation avoid in patients with seizure risk can improve appetite and sleep mirtazapine (Remeron) 7.5 mg 30 ma may cause thrombocytopenia Serotonin modulators trazodone (Desyrel) 75-150 mg helps insomnia at low doses 400 mg vilazodone (Viibryd) 10 mg 20 mg limited data in older adults vortioxetine (Trintellix) 5 ma 5-20 ma Tricyclic antidepressants (TCAs) may cause QTc prolongation, amitriptyline (Elavil) 25 mg 100-300 mg hypotension anticholineraic side effects limit nortriptyline (Pamelor) 25-50 mg 75-100 mg use in older patients

An approach to medication for depression^{4,5}



- Other augmentation strategies:
 - buspirone
 - lithium
 - antipsychotics

- Specialist referral is appropriate for persistent treatment resistant depression or at any stage if:
 - psychotic features
 - substance use disorder
 - suicidal risk

(1) Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2018;391(10128): 1357-1366. (2) Tedeschini E, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. *J Clin Psychiatry*. 2011;72(12):1660-1668. (3) Sobieraj DM, et al. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. *J Am Geriatr Soc*. 2019;67(8):1571-1581. (4) Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006;163(11):1905-1917. (5) Canadian Coalition for Seniors' Mental Health. *Canadian guidelines on prevention, assessment and treatment of depression among older adults: 2021 guideline update*.







Balanced information for better care

These are general recommendations only; specific clinical decisions should be made by the treating clinician based on an individual patient's clinical condition. These materials were made possible by the PACE Program of the Department of Aging of the Commonwealth of Pennsylvania. Links to references can be found at AlosaHealth.org.